GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00063544 | Liver | Cirrhotic | DNA-templated transcription, elongation | 35/4634 | 91/18723 | 2.56e-03 | 1.53e-02 | 35 |
GO:005149212 | Liver | Cirrhotic | regulation of stress fiber assembly | 35/4634 | 91/18723 | 2.56e-03 | 1.53e-02 | 35 |
GO:00196271 | Liver | Cirrhotic | urea metabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:0046185 | Liver | Cirrhotic | aldehyde catabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:006000911 | Liver | Cirrhotic | Sertoli cell development | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:00719411 | Liver | Cirrhotic | nitrogen cycle metabolic process | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:00900853 | Liver | Cirrhotic | regulation of protein deubiquitination | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:200011411 | Liver | Cirrhotic | regulation of establishment of cell polarity | 12/4634 | 22/18723 | 2.61e-03 | 1.53e-02 | 12 |
GO:0031116 | Liver | Cirrhotic | positive regulation of microtubule polymerization | 16/4634 | 33/18723 | 2.66e-03 | 1.56e-02 | 16 |
GO:00091446 | Liver | Cirrhotic | purine nucleoside triphosphate metabolic process | 34/4634 | 88/18723 | 2.68e-03 | 1.57e-02 | 34 |
GO:00063683 | Liver | Cirrhotic | transcription elongation from RNA polymerase II promoter | 28/4634 | 69/18723 | 2.70e-03 | 1.58e-02 | 28 |
GO:0050810 | Liver | Cirrhotic | regulation of steroid biosynthetic process | 28/4634 | 69/18723 | 2.70e-03 | 1.58e-02 | 28 |
GO:0006576 | Liver | Cirrhotic | cellular biogenic amine metabolic process | 38/4634 | 101/18723 | 2.72e-03 | 1.59e-02 | 38 |
GO:00988697 | Liver | Cirrhotic | cellular oxidant detoxification | 38/4634 | 101/18723 | 2.72e-03 | 1.59e-02 | 38 |
GO:003367312 | Liver | Cirrhotic | negative regulation of kinase activity | 78/4634 | 237/18723 | 2.73e-03 | 1.59e-02 | 78 |
GO:00091425 | Liver | Cirrhotic | nucleoside triphosphate biosynthetic process | 33/4634 | 85/18723 | 2.81e-03 | 1.63e-02 | 33 |
GO:00302246 | Liver | Cirrhotic | monocyte differentiation | 17/4634 | 36/18723 | 2.82e-03 | 1.63e-02 | 17 |
GO:00706702 | Liver | Cirrhotic | response to interleukin-4 | 17/4634 | 36/18723 | 2.82e-03 | 1.63e-02 | 17 |
GO:0070897 | Liver | Cirrhotic | transcription preinitiation complex assembly | 17/4634 | 36/18723 | 2.82e-03 | 1.63e-02 | 17 |
GO:19040191 | Liver | Cirrhotic | epithelial cell apoptotic process | 44/4634 | 121/18723 | 2.86e-03 | 1.65e-02 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |